Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × Sodium Chloride × Clear all

Phase

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Leukemia, Myeloid, Acute 4 Breast Neoplasms 4 Lung Neoplasms 3 Neoplasm Metastasis 2 Tissue Adhesions 1 Solid Tumor Refractory to Standard Therapy 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Platinum Resistant Ovarian Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Ototoxicity 1 Neutropenia 1 Neoplasms 1 Myoma 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphopenia 1 Locally Advanced Cervical Cancer 1 Limited Stage Small Cell Lung Cancer 1 Leiomyoma 1 Hearing Loss 1 Febrile Neutropenia 1 Fatigue 1 Digestive Tract 1

Interventions

pembrolizumab 146 Nivolumab 98 Ipilimumab 82 Dacarbazine 40 trametinib 34 dabrafenib 30 Vemurafenib 28 atezolizumab 21 binimetinib 19 Temozolomide 19 cemiplimab 16 Paclitaxel 15 cobimetinib 14 spartalizumab 13 encorafenib 12 Cisplatin 12 Carboplatin 12 Cyclophosphamide 10 talimogene laherparepvec 9 lenvatinib 9 durvalumab 9 Docetaxel 9 tremelimumab 8 relatlimab 8 Gemcitabine 8 Drug Therapy 8 Bevacizumab 8 Pemetrexed 7 Albumin-Bound Paclitaxel 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡